Balanced news tone
News Sentiment
KLRA sentiment intelligence
Kailera Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-10.3% over one week, -6.8% over four weeks, trend inactive, and near fair-value range.
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Up 96.0% in June
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Apr 2026 23:39
- Source
- MarketBeat
Kailera Therapeutics, Inc (KLRA) Stock Price Today: $19.30
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Apr 2026 00:22
- Source
- Gotrade
Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Reuters
Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Bloomberg.com
Obesity drug developer Kailera climbs on trading debut (KLRA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Seeking Alpha
Kailera Therapeutics (KLRA) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 00:20
- Source
- Stock Titan
Obesity drug developer Kailera sets $625M IPO, trading starts Friday
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Stock Titan
Kailera Therapeutics, Inc. Announces Pricing of Initial Public Offering at $16.00 Per Share
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Quiver Quantitative
symbol__ Stock Quote Price and Forecast
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 14 Apr 2026 16:38
- Source
- CNN
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Mar 2026 08:00
- Source
- Stocktwits
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Feb 2026 09:53
- Source
- Kavout | AI
Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- TIKR.com
Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 25 Feb 2026 08:00
- Source
- TIKR.com
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Feb 2026 08:00
- Source
- Barron's